Global Top 15 Companies Accounted for 25% of total Chemotheraphy market (QYResearch, 2021) | |
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles. Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment. The global key manufacturers of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs include Haisco, Mundipharma, Qilu Pharma, Merck, Heron Therapeutics, Teva, Helsinn, Mylan , Novartis , GSK, etc. In 2021, the global top five players had a share approximately 25.0% in terms of revenue. For more information, please contact the following e-mail address: Email: global@qyresearch.com Website: https://www.qyresearch.com | |
Target Nation: All Nations Target City : All Cities Last Update : 29 April 2024 4:28 AM Number of Views: 71 | Item Owner : Ann Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |